CN101790533B - 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂 - Google Patents

环丙基稠合的吲哚并苯并氮杂*hcv抑制剂 Download PDF

Info

Publication number
CN101790533B
CN101790533B CN2008800159152A CN200880015915A CN101790533B CN 101790533 B CN101790533 B CN 101790533B CN 2008800159152 A CN2008800159152 A CN 2008800159152A CN 200880015915 A CN200880015915 A CN 200880015915A CN 101790533 B CN101790533 B CN 101790533B
Authority
CN
China
Prior art keywords
alkyl
hcv
compound
cycloalkyl
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800159152A
Other languages
English (en)
Chinese (zh)
Other versions
CN101790533A (zh
Inventor
杨革新
约翰·A·本德
罗伯特·G·金特尔斯
杨忠
丁敏
涂勇
皮亚塞纳·休厄瓦萨姆
韩迎
约翰·F·卡多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101790533A publication Critical patent/CN101790533A/zh
Application granted granted Critical
Publication of CN101790533B publication Critical patent/CN101790533B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800159152A 2007-03-14 2008-03-13 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂 Expired - Fee Related CN101790533B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89488907P 2007-03-14 2007-03-14
US60/894,889 2007-03-14
US98952207P 2007-11-21 2007-11-21
US60/989,522 2007-11-21
PCT/US2008/056789 WO2008112851A1 (en) 2007-03-14 2008-03-13 Cyclopropyl fused indolobenzazepine hcv inhibitors

Publications (2)

Publication Number Publication Date
CN101790533A CN101790533A (zh) 2010-07-28
CN101790533B true CN101790533B (zh) 2013-02-27

Family

ID=39541177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800159152A Expired - Fee Related CN101790533B (zh) 2007-03-14 2008-03-13 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂

Country Status (6)

Country Link
US (1) US7538102B2 (OSRAM)
EP (1) EP2118110B1 (OSRAM)
JP (1) JP2010521483A (OSRAM)
CN (1) CN101790533B (OSRAM)
ES (1) ES2390191T3 (OSRAM)
WO (1) WO2008112851A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2375065T3 (es) * 2007-11-20 2012-02-24 Bristol-Myers Squibb Company Inhibidores de indilobenzazepina condensada con ciclopropilo de la ns5b del vhc.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP2011515496A (ja) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
EP2276764B1 (en) * 2008-03-27 2013-07-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
CN102659668B (zh) * 2012-05-03 2014-04-09 苏州汉德创宏生化科技有限公司 1-烷基-哌啶-4-磺酰苄胺的合成方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
BRPI0516972A (pt) 2004-10-26 2008-09-30 Angeletti P Ist Ricerche Bio composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2029606B1 (en) * 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2121694B1 (en) * 2007-03-13 2014-07-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Also Published As

Publication number Publication date
EP2118110B1 (en) 2012-07-25
US7538102B2 (en) 2009-05-26
JP2010521483A (ja) 2010-06-24
EP2118110A1 (en) 2009-11-18
US20080226592A1 (en) 2008-09-18
CN101790533A (zh) 2010-07-28
WO2008112851A1 (en) 2008-09-18
ES2390191T3 (es) 2012-11-07

Similar Documents

Publication Publication Date Title
CN101790533B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂
CN101730698B (zh) 用于治疗丙型肝炎的化合物
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101631790B (zh) 用于治疗丙型肝炎的化合物
CN101679442B (zh) 用于治疗丙型肝炎的化合物
CN101679441B (zh) 用于治疗丙型肝炎的化合物
US7547690B2 (en) Compounds for the treatment of Hepatitis C
CN101490054B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8129367B2 (en) Compounds for the treatment of Hepatitis C
CN101821268B (zh) 用于治疗丙型肝炎的四环化合物
CN101918412B (zh) 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物
KR20070049635A (ko) Ｈｃｖ 복제 저해제
CN101646674B (zh) 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物
CN101679437B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130227

Termination date: 20150313

EXPY Termination of patent right or utility model